

Haematologica
HAEMATOL/2018/188680
Version 3

Autologous T cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 MoAbs.

Esteban Enrique Elías, María Belén Almejún, Ana Colado, Gregorio Cordini, Maricel Vergara-Rubio, Enrique Podaza, Denise Risnik, María Cabrejo, Horacio Fernández-Grecco, Raimundo Fernando Bezares, María del Rosario Custidiano, Julio César Sánchez-Ávalos, Ángeles Vicente, Gonzalo Martín Garate, Mercedes Borge, Mirta Giordano, and Romina Gamberale

Disclosures: This work was supported by grants from Agencia Nacional de Promoción Científica y Tecnológica and CONICET. GR receives a Non-clinical Investigator Initiated Study (IIS) from Janssen, BRF and GR receive compensation as speakers for Janssen. GR receives compensation as speaker and as a consultant for Roche and Bristol Myers Squibb. BRF and CMR receive compensation as member of Advisory Board for Abbvie. The remaining authors declare no competing financial interests.

Contributions: EEE did most of the experiments and created the figures; AMB, CA, CG, VRM, PE, RD and BM contributed in the purification of CLL samples, in CD38 and CD49d determination by flow cytometry, in western blot and phagocytosis assays and in the analysis and interpretation of the data; CM, FGH, BRF, CMR, SAJC, VA and GMG provided patients samples and advice and contributed in the analysis and interpretation of the data; GM participated in the project conception and critically reviewed the manuscript, which was written by RG and EEE; RG designed and supervised the study.